Abstracts tagged "biomarkers and vasculitis"

Abstract Number: 1764 • 2018 ACR/ARHP Annual Meeting
The Utility of Serum Angiopoietin-1 and Angiopoietin-2 in Patients with Anti-Neutrophil Cytoplasmic Autoantibody-Associated Vasculitis
Yoko Wada¹, Takeshi Kuroda², Masaaki Nakano³ and Ichiei Narita¹, ¹Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan, ²Health Administration Center, Niigata University, Niigata, Japan, ³Department of Medical Technology, School of Health Sciences, Faculty of Medicine, Niigata University, Niigata, Japan
Background/Purpose: Angiopoietin-1 (Ang-1) and Angiopoietin-2 (Ang-2) are antagonistic ligands which bind with similar affinity to the extracellular domain of the tyrosine kinase with Ig-like and…
Abstract Number: 2741 • 2018 ACR/ARHP Annual Meeting
Candidate Biomarkers in ANCA-Associated Vasculitis Identified Using a Proteomic Approach
Paul A. Monach¹, Hemang Parikh², Laurie Conklin³, Jesse Damsker⁴, Peter C. Grayson⁵, David Cuthbertson⁶, Simon Carette⁷, Nader A. Khalidi⁸, Curry L. Koening⁹, Carol Langford¹⁰, Carol A. McAlear¹¹, Larry W. Moreland¹², Christian Pagnoux¹³, Philip Seo¹⁴, Ulrich Specks¹⁵, Antoine G. Sreih¹⁶, Steven R. Ytterberg¹⁷, Eric Hoffman⁴ and Peter A. Merkel¹⁸, ¹Rheumatology, VA Boston Healthcare System, Boston, MA, ²University of South Florida, Tampa, FL, ³ReveraGen BioPharma, Rockville, MD, ⁴ReveraGen Biopharma, Rockville, MD, ⁵National Institute of Arthritis, Musculoskeletal and Skin Disease, National Institutes of Health, Bethesda, MD, ⁶Biostatistics and Informatics, Department of Pediatrics, Department of Biostatistics and Informatics, Department of Pediatrics, University of South Florida, Tampa, FL, ⁷Division of Rheumatology, Mount Sinai Hospital, Toronto, ON, Canada, ⁸Rheumatology, McMaster University, Hamilton, ON, Canada, ⁹Rheumatology, Division of Rheumatology, University of Utah, Salt Lake City, UT, ¹⁰Rheumatic and Immunologic Diseases, Department of Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, ¹¹Division of Rheumatology, University of Pennsylvania; Perelman School of Medicine, Philadelphia, PA, ¹²Division of Rheumatology and Clinical Immunology, Division of Rheumatology, University of Pittsburgh, Pittsburgh, PA, ¹³Division of Rheumatology, Division of Rheumatology, Mount Sinai Hospital, Toronto, ON, Canada, ¹⁴Medicine, Division of Rheumatology, Johns Hopkins University, Baltimore, MD, ¹⁵Mayo Clinic College of Medicine, Rochester, MN, ¹⁶Rheumatology, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ¹⁷Rheumatology, Division of Rheumatology, Mayo Clinic College of Medicine, Rochester, MN, ¹⁸Division of Rheumatology and the Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Concentrations of many circulating proteins are elevated during severe, active ANCA-associated vasculitis (AAV). Finding biomarkers associated with milder disease, a more clinically relevant need,…
Abstract Number: 1764 • 2017 ACR/ARHP Annual Meeting
Small RNA Sequencing Shows Differential Plasma Microrna Expression in Patients with ANCA-Associated Vasculitis: A Pilot Study
Kevin Byram¹, Joseph F. Solus¹, Quanhu Sheng¹, Yan Guo¹, C Michael Stein¹ and Michelle J. Ormseth², ¹Vanderbilt University Medical Center, Nashville, TN, ²Rheumatology, Vanderbilt Medical Center, Nashville, TN
Background/Purpose: MicroRNAs (miRNAs) are small RNA molecules (~22 nucleotides) that participate in post-transcriptional gene regulation. miRNAs have potential both as biomarkers for diagnosis and prognosis…
Abstract Number: 1783 • 2017 ACR/ARHP Annual Meeting
The Value of a Combination of Serum Proteins to Identify Response to Induction Therapy Among Patients with ANCA-Associated Vasculitis
Sadao Jinno^1,2, S. Reza Jafarzadeh³, Roscoe Warner⁴, Ulrich Specks⁵, John H. Stone⁶, Gary S. Hoffman⁷, Cees G.M. Kallenberg⁸, Carol A. Langford⁹, Philip Seo¹⁰, Robert F. Spiera¹¹, E. William St Clair¹², Kent Johnson¹³, Peter A. Merkel¹⁴ and Paul A. Monach², ¹Rheumatology, Boston University School of Medicine, Boston, MA, ²Boston University School of Medicine, Boston, MA, ³Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston, MA, ⁴University of Michigan Medical School, Ann Arbor,, MI, ⁵Mayo Clinic College of Medicine, Rochester, MN, ⁶Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ⁷Rheumatology, Cleveland Clinic, Cleveland, OH, ⁸Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ⁹Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, ¹⁰Medicine, Johns Hopkins University, Baltimore, MD, ¹¹Rheumatology, Hospital for Special Surgery, New York, NY, ¹²Rheumatology, Duke University Medical Center, Durham, NC, ¹³University of Michigan Medical School, Ann Arbor, MI, ¹⁴Division of Rheumatology, University of Pennsylvania; Perelman School of Medicine, Philadelphia, PA
Background/Purpose: Most patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) achieve clinical remission after induction therapy. However, even among patients who achieve remission, induction therapy…
Abstract Number: 1847 • 2017 ACR/ARHP Annual Meeting
The IgG4:IgG RNA Ratio in Peripheral Blood Perfectly Differentiates Active Disease from Remission in Granulomatosis with Polyangiitis. a New Disease Activity Marker?
Aram Al-Soudi^1,2,3, Marieke E. Doorenspleet⁴, Rebecca Esveldt⁵, Lot Burgemeister⁵, Liesbeth Hak⁵, Sander W. Tas⁶, Ronald F van Vollenhoven⁷, Paul L. Klarenbeek^5,8 and Niek de Vries^5,9, ¹Dept of Experimental Immunology, Academic Medical Center, Amsterdam, Netherlands, ²Dept of Clinical Immunology & Rheumatology, ARC | Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ³Dept of Genome Analysis, Academic Medical Center, Amsterdam, Netherlands, ⁴ARC | Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ⁵Clinical Immunology & Rheumatology, ARC | Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ⁶Department of Clinical Immunology & Rheumatology and Laboratory for Experimental Immunology, ARC | Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ⁷Amsterdam Rheumatology and Immunology Center, Amsterdam, Netherlands, ⁸Dept. of Experimental Immunology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ⁹Laboratory of Experimental Immunology, Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands
Background/Purpose: Granulomatosis with Polyangiitis (GPA) is characterized by vasculitis in lungs, kidneys and the ear, nose and throat region. Regular monitoring and treatment adjustments are…
Abstract Number: 1862 • 2014 ACR/ARHP Annual Meeting
The Association of Low-Density Granulocytes with Disease Activity and Response to Treatment in ANCA-Associated Vasculitis
Peter C. Grayson¹, Carmelo Carmona-Rivera¹, Lijing Xu², Noha Lim², Adam Asare², Deborah J. Phippard², Mariana J. Kaplan³, Peter A. Merkel⁴ and Paul A. Monach⁵, ¹NIAMS Systemic Autoimmunity Branch, National Institutes of Health, Bethesda, MD, ²Immune Tolerance Network, Bethesda, MD, ³Systemic Autoimmunity Branch, Intramural Research Program, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁴University of Pennsylvania, Philadelphia, PA, ⁵Section of Rheumatology, Vasculitis Center, Boston University School of Medicine, Boston, MA
Background/Purpose: To discover new pathways involved in the pathophysiology of ANCA-associated vasculitis (AAV) and identify potential clinical biomarkers through use of whole-genome gene expression profiling.…
Abstract Number: 1860 • 2014 ACR/ARHP Annual Meeting
Serum Calprotectin and Disease Relapse in ANCA-Associated Vasculitis
Juliana B Draibe¹, Ruth J. Pepper¹, Peter A. Merkel², Alan D. Salama¹ and for The RAVE-ITN Investigators³, ¹Centre for Nephrology, University College London, London, United Kingdom, ²University of Pennsylvania, Philadelphia, PA, ³Immune Tolerance Network, San Franciscco, CA
Background/Purpose: In ANCA-associated vasculitis (AAV) disease relapses remain common but there are no reliable means to predict them. We previously demonstrated that serum calprotectin…
Abstract Number: 756 • 2013 ACR/ARHP Annual Meeting
Clinical Value Of Commonly-Measured Laboratory Tests In Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss)
Peter C. Grayson¹, Paul A. Monach², David Cuthbertson³, Simon Carette⁴, Gary S. Hoffman⁵, Nader A. Khalidi⁶, C. L. Koening⁷, Carol A. Langford⁸, Kathleen Maksimowicz-McKinnon⁹, Christian Pagnoux¹⁰, Philip Seo¹¹, Ulrich Specks¹², Steven R. Ytterberg¹³ and Peter A. Merkel¹⁴, ¹NIAMS, National Institutes of Health, Bethesda, MD, ²Rheumatology, Boston University, Boston, MA, ³Department of Biostatistics, University of South Florida, Tampa, FL, ⁴Division of Rheumatology, University of Toronto, Toronto, ON, Canada, ⁵Center for Vasculitis Care and Research, Cleveland Clinic Foundation, Cleveland, OH, ⁶Internal Medicine/Rheumatology, McMaster University, Hamilton, ON, Canada, ⁷Internal Medicine, Salt Lake City Veterans Administration, Salt Lake City, UT, ⁸Center for Vasculitis Care and Research, Cleveland Clinic, Cleveland, OH, ⁹Rheumatology, Henry Ford Hospital, Detroit, MI, ¹⁰Rheumatology, Mount Sinai Hospital, Toronto, Canada, Toronto, ON, Canada, ¹¹Rheumatology Division, Johns Hopkins Vasculitis Center, Johns Hopkins University, Baltimore, MD, ¹²Mayo Clinic, Rochester, MN, ¹³Rheumatology Division, Mayo Clinic, Rochester, MN, ¹⁴Division of Rheumatology, Vasculitis Center, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Serial measurement of absolute eosinophil count (Eos), serum immunoglobulin E (IgE), erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP) is common practice in the…
Abstract Number: 2380 • 2012 ACR/ARHP Annual Meeting
High Frequency of Ferritin Autoantibodies in Takayasu Arteritis
Niklas T. Baerlecken¹, Katherina Große², Frank Moosig³, Wolfgang L. Gross⁴, Reinhold E. Schmidt¹ and Torsten Witte⁵, ¹Clinical Immunology and Rheumatology, Medical University Hannover, Hannover, Germany, ²Department of Immunology and Rheumatology, Student, Hannover, Germany, ³University of Luebeck, Stormarnzing 156, Bad Bramstedt, Germany, ⁴Dept of Clinical Rheumatology, Medical University at Lubeck, Lubeck, Germany, ⁵Hannover Medical School, Hanover, Germany
Background/Purpose: Takayasu arteritis (TA) may be difficult to diagnose since diagnostic biomarkers have not been established so far. In a previous study, we could show…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].